Researchers from ten different countries shared the results of the successful completion of Phase III clinical trials for upadacitinib, a selective Janus kinase inhibitor. These trials were conducted among patients with severe alopecia areata.
According to the report, approximately half of the people participating in the study achieved significant improvement in scalp condition, reaching 80 percent hair coverage on the scalp.
Information regarding the progress and results of this study was officially published in the scientific journal JAMA Dermatology.

